Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol

Abstract

IntroductionSARS-CoV-2 (COVID-19) has caused an international pandemic of respiratory illness, resulting in significant healthcare and economic turmoil. To date, no robust vaccine or treatment has been identified. Elemental zinc has previously been demonstrated to have beneficial effects on coronaviruses and other viral respiratory infections due to its effect on RNA polymerase. Additionally, zinc has well-demonstrated protective effects against hypoxic injury—a clear mechanism of end-organ injury in respiratory distress syndrome. We aimed to assess the effect of high-dose intravenous zinc (HDIVZn) on SARS-CoV-2 infection. The end of study analyses will evaluate the reduction of impact of oxygen saturations or requirement of oxygen supplementation.Methods and analysisWe designed a double-blind randomised controlled trial of daily HDIVZn (0.5 mg/kg) versus placebo. Primary outcome measures are lowest oxygen saturation (or greatest level of supplemental oxygenation) for non-ventilated patients and worst PaO2/FiO2 for ventilated patients. Following power calculations, 60 hospitalised patients and 100 ventilated patients will be recruited to demonstrate a 20% difference. The duration of follow-up is up to the point of discharge.Ethics and disseminationEthical approval was obtained through the independent Human Research Ethics Committee. Participant recruitment will commence in May 2020. Results will be published in peer-reviewed medical journals.Trial registration numberACTRN126200000454976.

The effects of some essential and toxic metals/metalloids in COVID-19: A review

“…These researchers have reported that having low levels of serum zinc (< 50 μg/dL at the admission) is a risk factor that will determine the COVID-19 outcome, including a higher mortality. In turn, Perera et al (2020) conducted a double-blind randomized controlled trial of daily high-dose intravenous zinc (0.5 mg/kg) versus placebo. There were 160 hospitalized participants, including 100 critically ill patients with confirmed COVID-19.…”

Azithromycin Plus Zinc Sulfate Rapidly and Synergistically Suppresses IκBα-Mediated In Vitro Human Airway Cell ACE2 Expression for SARS-CoV-2 Entry

“…Rapid improvements in symptoms, including fever, dyspnea and hypoxia, were reported in a consecutive case series receiving high-dose zinc rescue with different preparations. (5) A randomized controlled trial for high-dose intravenous zinc was initiated as adjunctive therapy in SARS-CoV-2-positive critically ill patients (30). H322M was therefore treated with 24-hour serial doses of 18.75, 37.5, 75, 150 and 300 µM ZnSO4 (Zn) (Fig.…”

A pilot double‐blind safety and feasibility randomized controlled trial of high‐dose intravenous zinc in hospitalized COVID‐19 patients

“…A detailed clinical trial protocol has been published previously 19 . Briefly, we randomized consenting COVID‐19 confirmed hospitalized adults with oxygen saturation (SpO 2 ) of 94% or less while on ambient air to either daily HDIVZn or saline placebo.…”